X4 Pharmaceuticals, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 93
- Market Cap
- $117.9M
- Website
- http://www.x4pharma.com
Drug-Drug Interaction Potential of Mavorixafor
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT06914869
- Locations
- ๐บ๐ธ
Parexel International LLC, Baltimore, Maryland, United States
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT06858696
- Locations
- ๐บ๐ธ
Catalina Research Institute, LLC, Rialto, California, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธTexas Liver Institute/Alamo Medical Research, San Antonio, Texas, United States
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06056297
- Locations
- ๐บ๐ธ
Phoenix Children's Hospital, Phoenix, Arizona, United States
๐บ๐ธOrso Health, Torrance, California, United States
๐บ๐ธUniversity of Michigan, Ann Arbor, Michigan, United States
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04274738
- Locations
- ๐บ๐ธ
Colorado Blood Cancer Institute, Denver, Colorado, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMass General Hospital Cancer Center, Boston, Massachusetts, United States
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT04154488
- Locations
- ๐บ๐ธ
USF Health Department of Pediatrics, Saint Petersburg, Florida, United States
๐บ๐ธUniversity of Iowa Hospital and Clinics, Iowa City, Iowa, United States
๐บ๐ธUniversity of Michigan, Ann Arbor, Michigan, United States
Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03995108
- Locations
- ๐บ๐ธ
University of California San Diego Health/Rady Children's Hospital, San Diego, California, United States
๐บ๐ธCalifornia Dermatology Institute, Thousand Oaks, California, United States
๐บ๐ธUniversity of Iowa, Iowa City, Iowa, United States
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
- Conditions
- WHIM Syndrome
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- X4 Pharmaceuticals
- Registration Number
- NCT03087370
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT03005327
- Locations
- ๐บ๐ธ
University of Washington Medical Center, Seattle, Washington, United States
๐ฆ๐บSt. Vincent's Hospital, Fitzroy, Victoria, Australia
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2022-12-29
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02923531
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT02823405
- Locations
- ๐บ๐ธ
Clinical Site, Salt Lake City, Utah, United States